Anti-tumor effect of anti-PD-1 antibody against SCC3 tumor

Slides:

Advertisements

Similar presentations

Fig. 4-1, p Fig. 4-2, p. 109 Fig. 4-3, p. 110.

Advertisements

AB 11 22 33 44 55 66 77 88 99 10  20  19  18  17  16  15  14  13  12  11  21  22  23  24  25  26  27  28.

Fig. 16-CO, p Fig. 16-1, p. 450 Fig. 16-2, p. 450.

P.464. Table 13-1, p.465 Fig. 13-1, p.466 Fig. 13-2, p.467.

Fig. 11-1, p p. 360 Fig. 11-2, p. 361 Fig. 11-3, p. 361.

Table 6-1, p Fig. 6-1, p. 162 p. 163 Fig. 6-2, p. 164.

P Fig. 6-1, p. 193 Fig. 6-2, p. 193 Fig. 6-3, p. 195.

Figure 1.1 The observer in the truck sees the ball move in a vertical path when thrown upward. (b) The Earth observer views the path of the ball as a parabola.

Supplementary Figures&Legends. Figure1. Subcutaneous xenograft tumor models of the control group.

Slide 1Fig 28-CO, p.858. Slide 2Fig 28-1, p.859 Slide 3Fig Q28-19, p.884.

IMMUNOLOGY OF ABO AND RH BLOOD TYPES. EACH BLOOD TYPE IS NAMED ACCORDING TO THE ANTIGENS ON ITS SURFACE.

Normal skin tissue Supplementary Fig 1A KLF4 has a tumor suppressive function in human skin cancer. Skin cancer tissues were deparaffinized and IHC was.

The reading is 7.38 mm. The reading is 7.72 mm.

Supplementary Figure 1. A B C MP-MRT-AN KP-MRT-NS KP-MRT-RY KP-MRT-YM

GFP-RV IFN/GFP-RV GFP-RV IFN/GFP-RV A B CD 8 C CD 8 GFP GFP GFP-RV

Fig. 3. Expression of Ninj1protein in cortices of the ischemic hemispheres of the rat brain at 4 day post-MCAO. Coronal brain sections were prepared at.

From: Amitriptyline Suppresses Neuroinflammation-dependent Interleukin-10-p38 Mitogen-activated Protein Kinase-Heme Oxygenase-1 Signaling Pathway in Chronic.

Multiple Alleles Human Blood Types.

M.M. Wanke, M.V. Delpino, P.C. Baldi Theriogenology

Suppl. Fig. 1 A B C No tumor - +

Supplementary Fig. 1. PD transport parameters in C57 mice.

Fig. 2. Expression of Ninj1 in cortices of ischemic hemispheres of rat brains at 1 day post-MCAO. Coronal brain sections were prepared at 1 day post-MCAO.

A Untreated mM maphos, 48h 20 mM maphos, 48h 50 mM maphos, 48hh B

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Online Gifts Buy for wishes happy mother's day to yours choice and with happy gifts find here:

A B Supplementary figure S3 ShCtl ShLCoR LCoR mRNA (%) Optical density

A B C D CD4+ CD8+ Control Isotype Ab Anti-TNFa Ab Control Isotype Ab

Allison Hanlon, MD, PhD, June Kim, MD, David J. Leffell, MD

Volume 48, Issue 1, Pages (July 2005)

Diagnosis of celiac sprue

Supplementary Figure 1. Longitudinal study in a representative number of SLE patients one year before (t1), at the time (t2), and one year after renal.

A B C D E F Supplementary Fig. 1. Gating strategy for CD44+CD133+CD24+ B16 tumor initiating cells (TIC). Cells were gated on CD44. CD44 positive cells.

A B C D E F Supplementary Fig. 2. Gating strategy for CD44+CD24+ ID8agg tumor initiating cells (TIC). Cells were gated on CD44. CD44 positive cells were.

Hiding in Plain Sight: How Cancer Evades the Immune System

Triggering PD-1 in B cells suppresses tumor-specific immunity and promotes disease progression. Triggering PD-1 in B cells suppresses tumor-specific immunity.

Days after cell inoculation Days after cell inoculation

Days after cell inoculation Days after cell inoculation

Supplementary figure 1.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade

Figure 2S (Supplementary Data)

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Role of immune and inflammatory cells in lung cancer–associated PH

Clinical Assessment of Recombinant Human Follicle-Stimulating Hormone in Stimulating Ovarian Follicular Development Before In Vitro Fertilization fn1

Fig. 4 Surgery initiates a systemic inflammatory response that triggers the outgrowth of distant immunogenic tumors and can be inhibited by perioperative.

Fig. 6 Innate and adaptive immunity, but not ADCC, contributes to M7824 antitumor activity. Innate and adaptive immunity, but not ADCC, contributes to.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

C A B * * * * HCC1954 HCC1569 Supplementary-Figure S5 Tumor cells sc.

Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. (A)

Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts Bryce D Beseth, MD, Robert B Cameron, MD, Pamela Leland,

A B C D E F Supplementary Fig. 3. Gating strategy for ES2 ALDHhi tumor initiating cells (TIC). Cells were treated with the specific aldehyde dehydrogenase.

PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. MC38.

S.-H. Kung, S.-F. Wang, C.-W. Huang, C.-C. Hsu, H.-F. Liu, J.-Y. Yang

Antitumor efficacy of PI3K inhibitor NVP-BKM120 alone and in combination with olaparib. Antitumor efficacy of PI3K inhibitor NVP-BKM120 alone and in combination.

CD8 T cells play a critical role in responses of TILs due to BRAF inhibition. CD8 T cells play a critical role in responses of TILs due to BRAF inhibition.

mTORC1 is required to prevent cellular senescence.

Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c

Induction of cytotoxic activity in humanized SCC3 tumor-bearing mice treated with anti-PD-1 antibody. Induction of cytotoxic activity in humanized SCC3.

Kaplan–Meier curves for PFS and OS (for patients treated with anti-PD-1/PD-L1 monotherapy). Kaplan–Meier curves for PFS and OS (for patients treated with.

Dual blockade of PD-1 and CTLA-4 directly activates CD4+Foxp3− cells in the absence of CD8+ or CD4+Foxp3+ cells. Dual blockade of PD-1 and CTLA-4 directly.

Combination CDN and PD-L1 mAb treatment of established MOC1 tumors produces consistent tumor rejection. Combination CDN and PD-L1 mAb treatment of established.

CD4+ cells are required to generate protective immunity against the MT-HA tumor in HA104 mice. CD4+ cells are required to generate protective immunity.

Response of Calu-6 tumors to anti-VEGF therapy.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.

Moderate-affinity vaccine antigens elicited greatest antitumor response. Moderate-affinity vaccine antigens elicited greatest antitumor response. Wild-type.

Validation of KMT2D function in MM23, MM2, and MM25 PDXs

Supplementary Figure 1: AGS-22M6E ADC specific localization in tumor xenografts. AG-B1 tumor pieces were implanted in ICR-SCID mice subcutaneously.

Presentation transcript:

Anti-tumor effect of anti-PD-1 antibody against SCC3 tumor Supplementary Fig. 4A Anti-tumor effect of anti-PD-1 antibody against SCC3 tumor 4000 8000 12000 4 7 11 14 18 Control No.1 Control No.2 Control No.3 Control No.4 Control No.5 Control No.6 Tumor volume (mm3) 4000 8000 12000 4 7 11 14 18 Anti-PD-1Ab No.1 Anti-PD-1Ab No.2 Anti-PD-1Ab No.3 Anti-PD-1Ab No.4 Anti-PD-1Ab No.5 Anti-PD-1Ab No.6 Tumor volume (mm3) 2000 4000 6000 8000 4 7 11 14 18 Control Anti-PD-1Ab Tumor volume (mm3) Days after Ab injection

Anti-tumor effect of anti-PD-1 antibody against U87 tumor Supplementary Fig. 4B Anti-tumor effect of anti-PD-1 antibody against U87 tumor 2000 4000 6000 4 7 11 14 18 20 Control No.1 Control No.2 Control No.3 Control No.4 Tumor volume (mm3) 2000 4000 6000 4 7 11 14 18 20 Anti-PD-1Ab No.1 Anti-PD-1Ab No.2 Anti-PD-1Ab No.3 Anti-PD-1Ab No.4 Tumor volume (mm3) 1000 2000 3000 4000 4 7 11 14 18 20 Control Anti-PD-1Ab Tumor volume (mm3) Days after Ab injection